The NHS is investing over £10 million into a trial to study the effects of puberty blockers on trans adolescents, led by researchers at King’s College London. This initiative stems from recommendations in the Cass Report, aiming to fill existing knowledge gaps regarding the impacts of hormone therapy. The trial will involve administering puberty-suppressing hormones for over two years to young participants, focusing on their physical, emotional, and social well-being. This research follows previous bans on such medications in the UK, aiming to improve and expand clinical care for youth experiencing gender dysphoria.
The clinical research delivery arm of the NHS confirmed a trial into puberty blockers for trans adolescents, funded with over £10 million, to explore gender care.
The trial, part of the controversial Cass Report recommendations, will assess the physical, social and emotional impacts of puberty-suppressing hormones over two years.
Professor James Palmer emphasized that the research will provide evidence for diverse clinical care options for young people experiencing gender dysphoria.
The NHS aims to enhance services for children with gender incongruence, following the stringent recommendations of the Cass Review, despite prior bans on puberty blockers.
Collection
[
|
...
]